Marta Tufet Bayona’s Post

In this piece I am quoted about updated #COVID19 vaccines targeting different versions of omicron (JN.1 vs. KP.2) https://lnkd.in/ekCGN65j.

Uncover the Truth: How Dangerous Is Your COVID-19 Vaccine Batch? Understanding the Risks: Investigating COVID-19 Vaccine Batches The Vaccine Adverse Event Reporting System (VAERS) in the United States has unveiled alarming data regarding adverse reactions and deaths associated with specific COVID-19 vaccine batches. This discovery points to the existence of potentially deadly batches within the experimental vaccines. https://lnkd.in/eYbgCE8K

Is incidence of new-onset seizures after SARS-CoV-2 vaccines statistically different from the incidence among individuals not receiving SARS-CoV-2 vaccines? The answer in this Systematic Review: https://lnkd.in/dVR8yMHC

Qiming Venture Partners' portfolio company, CanSino Biologics (SEHK: 6185, SHSE: 688185), announced the initiation of a Phase 2/3 clinical trial for its adsorbed acellular pertussis, diphtheria, and tetanus (Tdcp) vaccine for adolescents and adults. This marks a major step forward and has already enrolled its first participant in Phase 2. Building on the successful completion of Phase 1, which demonstrated promising immunogenicity and a strong safety profile, this randomized, blinded, and controlled trial will further evaluate the vaccine's efficacy and safety. Designed for individuals aged 6 and above, the Tdcp vaccine addresses a critical unmet need, as China currently lacks an approved Tdcp booster for adolescents and adults. In contrast, such vaccines are part of routine immunization programs in many developed countries. If approved, this vaccine could fill a significant gap in China's vaccine market and make a meaningful impact on public health. #Vaccines #Biotech #ClinicalTrials #Immunization #PublicHealth #HealthcareInnovation #GlobalHealth #QimingPortfolio #QimingHealthcare

Our collection of biospecimens from vaccinated COVID-19 donors has surpassed 30,000! Central BioHub’s extensive inventory includes saliva samples from donors vaccinated with a diverse array of vaccines, including AstraZeneca (Vaxzevria), Johnson & Johnson, Moderna (Spikevax), Pfizer-BioNTech (Comirnaty), Sinopharm, Sputnik V, and more. Whether you're at the forefront of vaccine research, studying immune responses, or developing therapeutic targets, our biorepository is a crucial resource that can drive your project forward. Our samples are rigorously tested for SARS-CoV-2 and meticulously documented to enhance your research accuracy and efficiency. Why Choose Central BioHub's Biospecimens? ·     Detailed immunization profiles available. ·     Access to a vast and diverse collection of biospecimens. ·     All major and niche vaccines available for effectiveness studies. Find Vaccinated Donor (COVID-19) biospecimens for your research on our website: •          https://lnkd.in/eC4PcEuW #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine #Covid19

Stay informed with the latest updates on COVID-19 and MMR vaccines, along with a newly released study focusing on enhancing syphilis detection in the emergency department. https://lnkd.in/eJd-nRkw #COVID #covid19 #mpox #infectionprevention

Read today's updates on COVID-19 and Mpox vaccines and a study released today on doubling syphilis detection in the emergency department. https://lnkd.in/eJd-nRkw #COVID #covid19 #mpox #infectionprevention

In biotech and biopharma, we are hearing more and more about mRNA technology and vaccines. Following the approval of the COVID-19 mRNA vaccinations, companies are paying closer attention to the potential of mRNA therapies. This week, we dive into mRNA terminology and definitions, companies making a difference in the mRNA space, and more. Visit the article to learn more, https://lnkd.in/eEN6J2mF #mRNA #biotech #biopharma #vaccines #vaccinetherapy #bioprocessing

We are pleased to share our second quarter 2024 business and financial update as we continue to make significant strides in advancing our pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. We look forward to sharing VAX-31 adult Phase 1/2 study topline data in September, which will provide significant insights into the full potential of this vaccine candidate across the adult population.   Additionally, we expect to share VAX-24 infant Phase 2 study topline data by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025. We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market today.   Read more here: https://lnkd.in/g7J7ywWm #biotechnology #vaccines #publichealth

On May 17: Learn how vaccine developers in the Global South brought safe, affordable, and easy-to-store COVID-19 vaccines to market—and find out how we can ensure equitable access to life-saving vaccines during future pandemics and emergencies. Register now: https://lnkd.in/egpYXpVg